Karuna Therapeutics Inc

NASDAQ:KRTX  
80.80
+0.36 (+0.45%)
Regulatory, Other Pre-Announcement

Karuna Therapeutics Sees Topline Results From Phase 1B Trial Of Karxt In Early Q2 2021

Published: 10/07/2020 12:26 GMT
Karuna Therapeutics, Inc. (KRTX) - Karuna Therapeutics - Sees Topline Results From Phase 1b Clinical Trial Evaluating Safety & Tolerability of Karxt in Healthy Elderly Volunteers to Be Announced Early in Q2 2021.
Karuna Therapeutics - Earlier Expected Topline Results From Phase 1b Clinical Trial by End of 2020.
Karuna Therapeutics - Covid-19 Has Not Affected Anticipated Timing of Other Planned Clinical Trials.